Browse IKZF4

Summary
SymbolIKZF4
NameIKAROS family zinc finger 4 (Eos)
Aliases ZNFN1A4; zinc finger protein, subfamily 1A, 4 (Eos); ikaros family zinc finger protein 4; zinc finger transc ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain -
Function

DNA-binding protein that binds to the 5'GGGAATRCC-3' Ikaros-binding sequence. Transcriptional repressor. Interacts with SPI1 and MITF to repress transcription of the CTSK and ACP5 promoters via recruitment of corepressors SIN3A and CTBP2. May be involved in the development of central and peripheral nervous systems. Essential for the inhibitory function of regulatory T-cells (Treg). Mediates FOXP3-mediated gene silencing in regulatory T-cells (Treg) via recruitment of corepressor CTBP1 (By similarity).

> Gene Ontology
 
Biological Process -
Molecular Function GO:0008134 transcription factor binding
GO:0043425 bHLH transcription factor binding
GO:0046982 protein heterodimerization activity
Cellular Component GO:0005813 centrosome
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolIKZF4
NameIKAROS family zinc finger 4 (Eos)
Aliases ZNFN1A4; zinc finger protein, subfamily 1A, 4 (Eos); ikaros family zinc finger protein 4; zinc finger transc ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IKZF4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolIKZF4
NameIKAROS family zinc finger 4 (Eos)
Aliases ZNFN1A4; zinc finger protein, subfamily 1A, 4 (Eos); ikaros family zinc finger protein 4; zinc finger transc ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IKZF4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolIKZF4
NameIKAROS family zinc finger 4 (Eos)
Aliases ZNFN1A4; zinc finger protein, subfamily 1A, 4 (Eos); ikaros family zinc finger protein 4; zinc finger transc ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IKZF4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0750.719
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1770.752
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0060.991
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0650.805
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1370.935
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3250.87
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0620.822
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0910.926
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0160.988
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9190.167
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.420.113
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.050.396
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IKZF4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIKZF4
NameIKAROS family zinc finger 4 (Eos)
Aliases ZNFN1A4; zinc finger protein, subfamily 1A, 4 (Eos); ikaros family zinc finger protein 4; zinc finger transc ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IKZF4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIKZF4
NameIKAROS family zinc finger 4 (Eos)
Aliases ZNFN1A4; zinc finger protein, subfamily 1A, 4 (Eos); ikaros family zinc finger protein 4; zinc finger transc ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IKZF4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IKZF4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIKZF4
NameIKAROS family zinc finger 4 (Eos)
Aliases ZNFN1A4; zinc finger protein, subfamily 1A, 4 (Eos); ikaros family zinc finger protein 4; zinc finger transc ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IKZF4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIKZF4
NameIKAROS family zinc finger 4 (Eos)
Aliases ZNFN1A4; zinc finger protein, subfamily 1A, 4 (Eos); ikaros family zinc finger protein 4; zinc finger transc ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IKZF4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIKZF4
NameIKAROS family zinc finger 4 (Eos)
Aliases ZNFN1A4; zinc finger protein, subfamily 1A, 4 (Eos); ikaros family zinc finger protein 4; zinc finger transc ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IKZF4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIKZF4
NameIKAROS family zinc finger 4 (Eos)
Aliases ZNFN1A4; zinc finger protein, subfamily 1A, 4 (Eos); ikaros family zinc finger protein 4; zinc finger transc ......
Chromosomal Location12q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IKZF4 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.